12 - 18 May 2018
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
NICE approves injectable drugs for relapsing MS
NICE have approved all of the injectable disease modifying drugs for relapsing MS, other than Plegridy, which will be looked at separately, and Betaferon. NICE's initial suggestion was to only allow one drug (Extavia), but the companies brought their prices down to allow them to go through.
MS Trust link: NICE revises decision to restrict drugs for relapsing MS
Gilenya approved for young Americans
The US drug regulator, the FDA, has approved Gilenya (fingolimod) as a treatment for people aged 10 to 18 with relapsing MS - the first disease modifying drug for this age group. NICE will begin the process of assessing the drug for use with this age group by the NHS in England at the end of May
MS Trust link: Gilenya (fingolimod)
AAN meeting round up
A round up of topics covered April's meeting of the Academy of American Neurologists (AAN). Includes early vs later treatment, laquinimod, stem cells, Gilenya (fingolimod), childhood MS, new disease modifying drug guidelines, progression, biomarkers, cognition, telemedicine, fish, risk factors and puberty.
Source: National MS Society (USA)
MS Trust link: MS research updates